Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus

Thrombosis Research

Volumn 121, Issue 1, 2007, Pages 43-50

  Bulatova, Nailya R ^a   Yousef, Al Motassem F ^a   AbuRuz, Salah M ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Antiplatelet drugs; Cardiovascular disease prevention; Diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ADULT; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; BIVARIATE ANALYSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; JORDAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; JORDAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RISK FACTORS;

EID: 35649016092     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.03.006     Document Type: Article

References (33)

1. Alwan A., and King H. Diabetes in the Eastern Mediterranean (Middle East) region: the World Health Organization responds to a major public health challenge. Diabet Med 12 (1995) 1057-1058
2. Ajlouni K., Jaddou H., and Batieha A. Diabetes and impaired glucose tolerance in Jordan: prevalence and associated risk factors. J Intern Med 244 (1998) 317-323
3. Alwan A., ed. Health in Jordan. An outline of the current situation and the main challenges facing health development in Jordan. World Health Organization. Ministry of Health, Amman, Jordan; 2005.
4. Feskens E.J., and Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol 45 (1992) 1327-1334
5. Thomas R.J., Palumbo P.J., Melton III L.J., Roger V.L., Ransom J., O'Brien P.C., et al. Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970-1994. Arch Intern Med 163 (2003) 445-451
6. ETDRS I: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 268 (1992) 1292-1300
7. Gaspoz J.M., Coxson P.G., Goldman P.A., Williams L.W., Kuntz K.M., Hunink M.G., et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 346 (2002) 1800-1806
8. Nobles-James C., James E.A., and Sowers J.R. Prevention of cardiovascular complications of diabetes mellitus by aspirin. Cardiovasc Drug Rev 22 (2004) 215-226
9. Colwell JA: Aspirin therapy in diabetes (Technical review). Diabetes Care 20 (1997) 1767-1771
10. American Diabetes Association: Aspirin therapy in diabetes (Position Statement). Diabetes Care 20 (1997) 1772-1773
11. Guidelines for Diabetes Care. International Diabetes Federation. European Region. Diabetic Medicine 16 (1999) 23
12. American Diabetes Association: aspirin therapy in diabetes (Position Statement). Diabetes Care 23 SV1 (2000) S61-S62
13. American Diabetes Association: aspirin therapy in diabetes. Diabetes Care 26 SV1 (2003) S87-S88
14. Harrington R.A., Becker R.C., Ezekowitz M., Meade T.W., O'Connor C.M., Vorchhelmer D.A., et al. Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 SV3 (2004) 513S-548S
15. CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348 (1996) 1329-1339
16. Stafford R.S. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 101 (2000) 1097-1101
17. Rolka D.B., Fagot-Campagna A., and Narayan K.M. Aspirin use among adults with diabetes:estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 24 (2001) 197-201
18. McFarlane S.I., Jacober S.J., Winer N., Kaur J., Castro J.P., Wui M.A., et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 25 (2002) 718-723
19. Nguyen K.X., Marinac J.S., and Sun C. Aspirin for primary prevention in patients with diabetes mellitus. Fam Med 37 (2005) 112-117
20. Miller S.R., Littenberg B., and MacLean C.D. Prevalence of antiplatelet therapy in patients with diabetes. Cardiovascular Diabetology 4 (2005) 18
21. Persell S.D., and Baker D.W. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med 164 (2004) 2492-2499
22. Pyorala K., Lehto S., De Bacquer D., De Sutter J., Sans S., Keil U., et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I and II surveys. Diabetologia 47 (2004) 1257-1265
23. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST segment-elevation myocardial infarction: Summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
24. Smith Jr. S.C., Dove J.T., Jacobs A.K., Kennedy J.W., Kereiakes D., Kern M.J., et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). Am Coll Cardiol 37 (2001) 2215-2239
25. Mehta S.S., Silver R.J., Aaronson A., Abrahamson M., and Goldfine A.B. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97 4 (2006) 567-570
26. Fateh-Moghadam S., Plockinger U., Cabeza N., Htun P., Reuter T., Ersel S., et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42 2 (2005) 99-103
27. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 119 SV1 (2001) 300S-320S
28. Albers G.W., Hart R.G., Lutsep H.L., Newell D.W., and Sacco R.L. AHA scientific statement. Supplement to guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attack, Stroke Council, American Heart Association. Stroke 30 (1999) 2502-2511
29. Legato M.J., Gelzer A., Goland R., Ebner S.A., Rajan S., Villagra V., et al. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 3 2 (2006) 131-158
30. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
31. Hennekens C.H., Dyken M.L., and Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 96 (1997) 2751-2753
32. Yudkin J.S. Which diabetic patients should be taking aspirin?. BMJ 311 (1995) 641-642
33. McLaughlin T.J., Soumerai S.B., Willison D.J., Gurwitz J.H., Borbas C., Guadagnoli E., et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med 156 (1996) 799-805